

#6

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Svendsen et al.

Serial No.: To be assigned

Group Art Unit: To be assigned

Filed: June 3, 1999

Examiner: To be assigned

For:  $\alpha$ -Amylase Mutants



**INFORMATION DISCLOSURE STATEMENT**

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants cite references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The references are listed in PTO form 1449 which is in accordance with the requirements of M.P.E.P. 609. These references were cited by the Examiner for USSN 08/600,908 filed February 13, 1996, the benefit of which is claimed under 35 USC 120.


The references are as follows:

1. Machius et al., (1995) J. Mol. Biol. 246:545-559 (Office Action dated 12/8/98)
2. MacGregor (1988) J. Protein Chemistry 7:399-415 (Office Action dated 8/20/97)
3. Suzuki et al., (1989) J. Biol. Chem. 264:18933-18938 (Office Action dated 8/20/97)

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached references.

Respectfully submitted,

Date: June 3, 1999



---

Reza Green, Reg. No. 38,475  
Novo Nordisk of North America, Inc.  
405 Lexington Avenue, Suite 6400  
New York, NY 10174-6401  
(212) 867-0123